Publications by authors named "M D Garcia-de-Lucas"
Although, in randomized clinical trials, once-weekly subcutaneous semaglutide (OW s.c.) has demonstrated superior efficacy in comparison with placebo and active controls in terms of glycemic control and body weight reduction in patients with type 2 diabetes mellitus (T2DM), these results need to be confirmed in a real-world (RW) setting.
View Article and Find Full Text PDFAim: To reach a multidisciplinary consensus on managing patients with type 2 diabetes among specialists in family medicine, cardiology, endocrinology, internal medicine, and nephrology.
Methods: A two-round Delphi study was conducted using a questionnaire with 68 positive/negative statements distributed in four thematic blocks on diabetes management: early diagnosis and prediabetes, referral criteria, treatment and comorbidities, and clinical management. The expert panel was composed of 105 physicians from different specialties (family medicine, cardiology, endocrinology, internal medicine, and nephrology) with experience in managing patients with diabetes and who were members of a diabetes-related society.
Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
Front Endocrinol (Lausanne)
November 2023
Article Synopsis
- Semaglutide is an effective treatment for glycemic control and weight loss in type 2 diabetes (T2D) patients, including those with chronic kidney disease (CKD), showing no significant safety concerns over a 12-month period.
- In a study comparing T2D patients with and without CKD, both groups experienced reduced HbA1c levels and weight loss, although non-CKD patients lost slightly more weight.
- CKD severity had minimal impact on treatment efficacy and safety, suggesting that semaglutide can be safely used in T2D patients with varying levels of kidney function.
Background: The aim of this study is to investigate the use of once-weekly semaglutide in a real population of patients with type 2 diabetes mellitus (T2DM) over 70 years in two Spanish hospitals.
Methods: An observational, retrospective, and multicenter clinical study was designed. It included 60 patients with T2DM, with a mean age of 76.